retatrutide clinical trial phase retatrutide The drug is manufactured by Eli Lilly and is not FDA approved, however, one person gained access to the prescription through a program that approves experimental treatments for patients traditionally suffering Eli Lilly infiltrates anti-obesity market

Not all patients experience side effects, and treatment tolerance varies

Prevention and Mitigation of Nutrient Deficiencies Dietary guidance for individuals using GLP-1s should focus on ensuring nutrient adequacy within an often substantially lower-calorie diet

GLP-1 RA drugs have been cited to suppress neuroinflammation and be neuroprotective both in the eye and the brain

doi: 10.1111/apt.15316

Rapid or significant calorie restriction, especially if nutritionally unbalanced, may result in inadequate intake of essential minerals and vitamins

All participants received counseling on dietary and exercise behaviors, including education on achieving a daily caloric deficit of 500-750 kcal